Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological responses and adverse reactions of heterologous BNT162b2 second booster after two-dose CoronaVac in healthcare workers
TCTR20221112001Phase 3Recruiting
- Sponsor
- National Science, Research and Innovation Fund
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by National Science, Research and Innovation Fund. Started Sep 2021; status: recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221112001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221112001.